The FDA granted accelerated approval to Ascendis Pharma’s TransCon CNP (now Yuviwel), a once‑weekly injection for children with achondroplasia two years and older, ending BioMarin’s de facto monopoly on the indication. The approval was based on improvements in annualized growth velocity and comes with confirmatory post‑marketing obligations. Ascendis expects to make the drug available through prescribing physicians in Q2 and has not yet disclosed pricing. Analysts predict modest 2026 uptake but note potential for greater market share over time because of the weekly dosing convenience relative to BioMarin’s daily product. The approval tightens competition in a small but lucrative pediatric market and underscores the FDA’s willingness to use accelerated pathways where growth metrics are accepted as surrogate markers, contingent on confirmatory trials.